Prévention osseuse dans le traitement du cancer de la prostate

25 mars 2011

Auteurs : Th. Bessede
Référence : Prog Urol, 2011, 21, S58, suppl. S2




 



Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser



Références



Kinnane N. Burden of bone disease Eur J Oncol Nurs 2007 ;  11 (Suppl 2) : S28-S31
Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation Nature 2003 ;  423 : 337-342 [cross-ref]
Colombel M. [Prescription of bisphosphonates in prostate cancer] Prog Urol 2008 ;  18 : F5-F7 [inter-ref]
Smith M.R., Goode M., Zietman A.L., McGovern F.J., Lee H., Finkelstein J.S. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition J Clin Oncol 2004 ;  22 : 2546-2553 [cross-ref]
Smith M.R., Lee W.C., Brandman J., Wang Q., Botteman M., Pashos C.L. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer J Clin Oncol 2005 ;  23 : 7897-7903 [cross-ref]
Smith M.R., Eastham J., Gleason D.M., Shasha D., Tchekmedyian S., Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer J Urol 2003 ;  169 : 2008-2012 [cross-ref]
Lebret T., Mejean A. Physiopathology, diagnosis and management of bone metastases from prostate cancer Prog Urol 2008 ;  18 : S349-S356
Bhoopalam N., Campbell S.C., Moritz T., Broderick W.R., Iyer P., Arcenas A.G., et al. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy J Urol 2009 ;  182 : 2257-2264 [cross-ref]
Michaelson M.D., Kaufman D.S., Lee H., McGovern F.J., Kantoff P.W., Fallon M.A., et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer J Clin Oncol 2007 ;  25 : 1038-1042 [cross-ref]
Roodman G.D. Mechanisms of bone metastasis N Engl J Med 2004 ;  350 : 1655-1664 [cross-ref]
Smith M.R., Egerdie B., Hernandez Toriz N., Feldman R., Tammela T.L., Saad F., et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer N Engl J Med 2009 ;  361 : 745-755 [cross-ref]
Durand X., Xylinas E., Ploussard G., De la Taille A. Urinary biomarkers in prostate cancer: an update Prog Urol 2010 ;  20 : 1184-1191 [inter-ref]
Mundy G.R. Bisphosphonates as cancer drugs Hosp Pract (Minneap) 1999 ;  34 : 81-848–9 93–4.
Saad F., Gleason D.M., Murray R., Tchekmedyian S., Venner P., Lacombe L., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 2002 ;  94 : 1458-1468 [cross-ref]
Saad F., Karakiewicz P., Perrotte P. The role of bisphosphonates in hormone-refractory prostate cancer World J Urol 2005 ;  23 : 14-18 [cross-ref]
Beuzeboc P., Soulie M., Richaud P., Salomon L., Staerman F., Peyromaure M., et al. Fusion genes and prostate cancer. From discovery to prognosis and therapeutic perspectives Prog Urol 2009 ;  19 : 819-824 [inter-ref]
Soulie M., Beuzeboc P., Cornud F., Eschwege P., Gaschignard N., Grosclaude P., et al. Prostatic cancers Prog Urol 2007 ;  17 : 1159-1230
Dearnaley D.P., Mason M.D., Parmar M.K., Sanders K., Sydes M.R. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials Lancet Oncol 2009 ;  10 : 872-876 [inter-ref]
Fizazi K. A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer  Chicago: ASCO (2010). #4507.
Giraudo E., Inoue M., Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis J Clin Invest 2004 ;  114 : 623-633 [cross-ref]
Sato K., Kimura S., Segawa H., Yokota A., Matsumoto S., Kuroda J., et al. Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy Int J Cancer 2005 ;  116 : 94-99 [cross-ref]






© 2011 
Elsevier Masson SAS. Tous droits réservés.